Connect
MJA
MJA

Do advertisements in clinical software influence prescribing?

Peter R Mansfield
Med J Aust 2008; 188 (1): . || doi: 10.5694/j.1326-5377.2008.tb01496.x
Published online: 7 January 2008

Pharmaceutical companies must believe there are benefits from advertising, but just what these benefits are, and how they are measured, is not clear

Pharmaceutical company executives must believe that advertising is effective. Otherwise, pharmaceutical advertising would be illegal under the Australian Corporations Act 2001 (Cwlth), which requires that company staff rationally believe their business judgements to be in the best interests of their corporation.1 However, Henderson and colleagues’ study in this issue of the Journal may have found an advertising delivery channel that does not work (→ The effect of advertising in clinical software on general practitioners' prescribing behaviour).2 They compared prescribing by general practitioners exposed to advertisements in clinical software with prescribing by unexposed GPs during 2003–2005. Despite a large sample size and carefully controlling for many possible confounders, they did not detect any significant difference in prescribing for six of the seven drugs studied. Interestingly, there was significantly less prescribing of one drug by exposed GPs — possibly a false-positive finding arising by chance, but this is the first ever published evidence that pharmaceutical advertising may sometimes unintentionally reduce sales.


  • 1 Discipline of General Practice, University of Adelaide, Adelaide, SA.
  • 2 Healthy Skepticism Inc, Willunga, SA.



  • 1. Australian Government Corporation and Markets Advisory Committee. The social responsibility of corporations. Canberra: The Committee, 2006. http://www.camac.gov.au/camac/camac.nsf/byHeadline/PDFFinal+Reports+2006/$file/CSR_Report.pdf (accessed Sep 2007).
  • 2. Henderson J, Miller G, Pan Y, Britt H. The effect of advertising in clinical software on general practitioners’ prescribing behaviour. Med J Aust 2008; 188: 15-20. <MJA full text>
  • 3. Wanamaker’s. Wikipedia, the free encyclopedia. http://en.wikipedia.org/wiki/Wanamaker%27s (accessed Sep 2007).
  • 4. Lidstone J, Collier T. Marketing planning for the pharmaceutical industry. Aldershot, UK: Gower, 1987.
  • 5. Garai PR. Advertising and promotion of drugs. In: Talalay P, editor. Drugs in our society. Baltimore: Johns Hopkins University Press, 1964. http://www.healthyskepticism.org/publications/editions/2003/10.php (accessed Sep 2007).
  • 6. Wittink D. Analysis of ROI for pharmaceutical promotion (ARPP). RxPromoROI, 2002. http://www.rxpromoroi.org/arpp/media/arpp_handout_0927.pdf (accessed Sep 2007).
  • 7. Harvey KJ, Vitry AI, Roughead E, et al. Pharmaceutical advertisements in prescribing software: an analysis. Med J Aust 2005; 183: 75-79. <MJA full text>
  • 8. Mansfield PR. Healthy Skepticism’s new AdWatch: understanding drug promotion. Med J Aust 2003; 179: 644-645. <MJA full text>
  • 9. Petty RE, Wegener DT. The elaboration likelihood model: current status and controversies. In: Chaiken S, Trope Y, editors. Dual process theories in social psychology. New York: Guilford Press, 1999: 41-72.
  • 10. Manchanda P, Chintagunta P. Responsiveness of physician prescription behaviour to salesforce effort: an individual level analysis. Marketing Letters 2004; 15: 129-145.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.